• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news

FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Home Based Primary Care for Patients with Sickle Cell Disease
Conclusion: Overall, home based primary care seems to be a promising alternative for pts with SCD. It had a significant impact on patient quality of care and may improve prescription adherence, but more data are needed to determine if it has an effect on healthcare utilization for pts with SCD.DisclosuresMoore: Ohio State University College of Medicine: Research Funding. Desai: FDA: Research Funding; Pfizer: Research Funding; University of Pittsburgh: Research Funding; Selexy/Novartis: Research Funding; NIH: Research Funding; Ironwood: Other: Adjudication Committee.
Source: Blood - November 21, 2018 Category: Hematology Authors: Moore, M. D., Schamess, A., Williams, N., Huang, Y., Menka, G., Desai, P. C. Tags: 901. Health Services Research-Non-Malignant Conditions: Poster III Source Type: research

An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015
Conclusions: These results, along with the safety data from the prelicensure clinical trials, confirm that the HPV4 vaccine has a favorable safety profile. Key policy, medical and regulatory organizations around the world have independently reviewed these data and continue to recommend routine HPV vaccination.
Source: The Pediatric Infectious Disease Journal - August 14, 2015 Category: Infectious Diseases Tags: Vaccine Reports Source Type: research

157 E-Books New to JEFFLINE
Scott Library added these 157 e-books to the growing collection in May and June: Accurate Results in the Clinical Laboratory Adult Emergency Medicine Adult-Gerontology and Family Nurse Practitioner Certification Examination (4th ed.) Advanced Assessment: Interpreting Findings and Formulating Differential Diagnoses (2nd ed.) Advancing Your Career: Concepts of Professional Nursing (5th ed.) Arrhythmia Essentials Atlas of Advanced Operative Surgery Atlas of Clinical Neurology (3rd ed.) Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches Atlas of Human Infectious Diseases Atlas of No...
Source: What's New on JEFFLINE - June 25, 2013 Category: Databases & Libraries Authors: Gary Kaplan Tags: All News Clinicians Researchers Students Teaching Faculty Source Type: news